Key facts
- This page summarizes Stephen Davis's Form 4 filing for HERON THERAPEUTICS, INC. /DE/ (HRTX).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 20 Dec 2022, 16:19.
Stephen Davis - 16 Dec 2022 Form 4 Insider Report for HERON THERAPEUTICS, INC. /DE/ (HRTX)
- Reporting relationship
- Director
- Issuer ticker
- HRTX
- Reported as of
- 16 Dec 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 20 Dec 2022, 16:19:23 UTC
- Prior SEC filing
- 18 Oct 2022
- Next SEC filing
- 05 Jan 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Lisa Peraza Attorney-in-fact for Stephen Davis
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Stephen Davis filed Form 4 for HERON THERAPEUTICS, INC. /DE/ (HRTX) on 20 Dec 2022.
Change
- Previous filing in this sequence was filed on 18 Oct 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
HRTX
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +38,580
- Change %
- +287%
- Price
- $0.000000
- Shares after
- 52,032
- Date
- 16 Dec 2022
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
HRTX
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +77,160
- Change %
- Price
- $0.000000
- Shares after
- 77,160
- Date
- 16 Dec 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 77,160
- Exercise price
- $2.74
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The shares were granted as restricted stock units which vest in full on December 16, 2023.
Footnote F2
The stock options vest and become exercisable in 12 equal monthly installments beginning one month after the date of grant.